Globus MedicalGMED
Market Cap: $9.48B
About: Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.
Employees: 5,000
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
416% more call options, than puts
Call options by funds: $16.1M | Put options by funds: $3.12M
38% more funds holding in top 10
Funds holding in top 10: 16 [Q1] → 22 (+6) [Q2]
28% more capital invested
Capital invested by funds: $6.02B [Q1] → $7.72B (+$1.71B) [Q2]
16% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 57
2% more funds holding
Funds holding: 434 [Q1] → 443 (+9) [Q2]
0.85% more ownership
Funds ownership: 99.29% [Q1] → 100.15% (+0.85%) [Q2]
18% less repeat investments, than reductions
Existing positions increased: 136 | Existing positions reduced: 166
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
BTIG Ryan Zimmerman 56% 1-year accuracy 19 / 34 met price target | 10%upside $77 | Buy Maintained | 28 Aug 2024 |
Barclays Matt Miksic 59% 1-year accuracy 17 / 29 met price target | 33%upside $93 | Overweight Maintained | 8 Aug 2024 |
RBC Capital Shagun Singh 69% 1-year accuracy 43 / 62 met price target | 11%upside $78 | Outperform Maintained | 7 Aug 2024 |
Truist Securities Richard Newitter 67% 1-year accuracy 29 / 43 met price target | 13%upside $79 | Hold Maintained | 7 Aug 2024 |
Wells Fargo Vik Chopra 20% 1-year accuracy 1 / 5 met price target | 11%upside $78 | Overweight Upgraded | 7 Aug 2024 |
Financial journalist opinion
Based on 91 articles about GMED published over the past 30 days